Sonelokimab (ALX 0761, M 1095) is a trivalent nanobody combining monovalent camelid-derived nanobodies targeting human interleukin (IL)-17A and IL-17F with human serum albumin VHHs, presenting it as a promising candidate for investigating plaque-type psoriasis treatments [1] [2].
CAS Number:
[1414386-05-2]
Target:
Interleukin|||MMP
* VAT and and shipping costs not included. Errors and price changes excepted
